"{\n \"business_address\": \"777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY 10591\", \n \"business_phone_no\": \"9143477000\", \n \"ceo\": \"Leonard S. Schleifer\", \n \"cik\": \"0000872589\", \n \"company_url\": \"www.regeneron.com\", \n \"employees\": 5400, \n \"entity_legal_form\": \"INCORPORATED\", \n \"entity_status\": null, \n \"hq_address1\": null, \n \"hq_address2\": null, \n \"hq_address_city\": null, \n \"hq_address_postal_code\": null, \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"New York\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"New York\", \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Biotechnology\", \n \"latest_filing_date\": \"2017-08-03\", \n \"legal_name\": \"REGENERON PHARMACEUTICALS INC\", \n \"lei\": \"549300RCBFWIRX3HYQ56\", \n \"long_description\": \"Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.\", \n \"mailing_address\": \"777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY 10591\", \n \"name\": \"Regeneron Pharmaceuticals Inc\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000C734W3\", \n   \"composite_figi_ticker\": \"REGN:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNAS\", \n   \"figi\": \"BBG000C75K91\", \n   \"figi_exch_cntry\": \"UW\", \n   \"figi_ticker\": \"REGN:UW\", \n   \"figi_uniqueid\": \"EQ0010647000001000\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNAS\", \n   \"primary_listing\": true, \n   \"security_name\": \"REGENERON PHARMACEUTICALS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"NASDAQ\", \n   \"ticker\": \"REGN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000HCYYG5\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"RGO:GR\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"RGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TLTK39\", \n   \"composite_figi_ticker\": \"REGN1:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG006TLTK57\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"REGN1:SE\", \n   \"figi_uniqueid\": \"EQ0000000036705129\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"REGN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000HCYZV5\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"RGO:GF\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"RGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG007257HC2\", \n   \"composite_figi_ticker\": \"REGNEUR:XA\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XWBO\", \n   \"figi\": \"BBG007257HW0\", \n   \"figi_exch_cntry\": \"XA\", \n   \"figi_ticker\": \"REGNEUR:XA\", \n   \"figi_uniqueid\": \"EQ0000000037270039\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XWBO\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"WBO\", \n   \"ticker\": \"REGN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000HCZ327\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"RGO:GM\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"RGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000HCZ3H1\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"RGO:GB\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"RGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000HCZ112\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"RGO:GD\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"RGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XHAM\", \n   \"figi\": \"BBG000HCYYG5\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"RGO:GR\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XHAM\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"HAM\", \n   \"ticker\": \"RGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TLTK39\", \n   \"composite_figi_ticker\": \"REGN1:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBRN\", \n   \"figi\": \"BBG006TLTK93\", \n   \"figi_exch_cntry\": \"BW\", \n   \"figi_ticker\": \"REGN1:BW\", \n   \"figi_uniqueid\": \"EQ0000000036705129\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBRN\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"BRN\", \n   \"ticker\": \"US75886F1075\"\n  }, \n  {\n   \"composite_figi\": \"BBG000HCYYG5\", \n   \"composite_figi_ticker\": \"RGO:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000HCZ2Q3\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"RGO:GS\", \n   \"figi_uniqueid\": \"EQ0010647000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"REGENERON PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S6PX49\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"RGO\"\n  }\n ], \n \"short_description\": \"Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. Its products include EYLEA injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST, which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and PRALUENT Injection for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C. Regeneron Pharmaceuticals was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.\", \n \"sic\": 2834, \n \"standardized_active\": true, \n \"stock_exchange\": \"NasdaqGS\", \n \"template\": \"industrial\", \n \"ticker\": \"REGN\"\n}"